On the other hand, other immune cells have also been implicated in anti-tumor effects, such as CD4+-dependent anti-tumor effects [66] and innate lymphocytes (ILC2), which are anticancer immune cells in PCa immunotherapy and emerge as tissue-specific enhancers of cancer immunity that amplify the efficacy of anti-PD-1 immunotherapy [64]. Here, CD4 is linked to cancer.